Indigo Diabetes N.V.: Indigo Diabetes Appoints Paul Moraviec as Chairman of the Board
Brings decades of leadership experience in the Global MedTech sector
As CEO of ConvaTec Group Plc,
led the $
Transformed Abbott s Diabetes Care EMEA division
BELGIUM - Ghent, May
2
, 2021 - Indigo Diabetes N.V. ( Indigo or the Company ), a pioneering developer of medical solutions using nanophotonics, is pleased to announce the appointment of Paul Moraviec as Chairman of its Board of Directors.
Paul has amassed over three decades of global experience in the healthcare sector, having held multiple senior leadership positions. Most recently Paul led the ConvaTec Group Plc, a global medical products and technologies company, as Chief Executive Officer, orchestrating a successful company turnaround and subsequent $4.5 billion IPO on the London Stock Exchange in 2016, which at the time was the largest healthcare listing in Europe.
Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress
May 12, 2021 on track for
Phase III European trial in stage IIIB/C melanoma. Opening of additional clinical centers to boost recruitment rate is ongoing. E
Fibromun
Philogen is well capitalized, about
th the
here (https://us06web.zoom.us/webinar/register/WN nEuoFxsHTXSTdtS4RBslYg)
Siena (Italy), 12 May 2021 - (Globe Newswire) - Philogen S.p.A. (BIT:PHIL) - a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce progress updates for its fully-owned immunocytokine and small molecule programs.
- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned - London, UK 11 May 2021 - Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2021 and recent business highlights. Achilles made significant progress in the first quarter of 2021. We reported the first clinical data from our ongoing CHIRON and THETIS trials evaluating our precision TIL cNeT therapy in patients with non-small cell lung cancer and melanoma, respectively, and priced our successful US initial public offering on Nasdaq, which closed just after quarter-end, said Dr Iraj Ali, Chief Executive Officer of Achilles. We continue to enroll and dose patients and have
Omne Possibile launched to harness transformative power of XNA in healthcare, information technology and smart materials
information technology
creating
XNA
the
forefront of the synthetic biology revolution, forecast to transform medicine, agriculture, energy, consumer products and IT with a $4 trillion annual economic
impact
h
-
May
2021: Omne Possibile ( the Company ), a global synthetic biology company pioneering the XNA revolution, has been launched today to harness the power of XNA (xeno nucleic acids) to transform medicine, agriculture, energy, consumer products and information technology. XNA is at the forefront of the synthetic biology revolution, designed to overcome the constraints of the chemical structures of DNA and RNA technologies. It is forecast to have a $4 trillion annual economic impact over the next 10 to 20 years, greater than that of the internet.
About Sensyne Health www.sensynehealth.com Sensyne Health plc Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers r emote patient monitoring and real-time decision-making systems for healthcare organizations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines. About MagnifEye About MagnifEye MagnifEye is Sensyne s proprietary cloud-based software application, available as both a smartphone app and a web application, that uses advanced, proprietary deep learning algorithms developed by the Company